Core Insights - Yuyue Medical reported a third-quarter revenue of 1.886 billion yuan, representing a year-on-year growth of 9.63% [1] - The company's net profit attributable to shareholders for the third quarter was 263 million yuan, showing a year-on-year decline of 35.99% [1] - For the first three quarters, Yuyue Medical achieved a revenue of 6.545 billion yuan, which is an 8.58% increase compared to the same period last year [1] - The net profit attributable to shareholders for the first three quarters was 1.466 billion yuan, reflecting a year-on-year decrease of 4.28% [1]

Core Insights - Yuyue Medical, a leading domestic medical device company, reported a revenue of 6.545 billion yuan for the first three quarters of 2025, marking an 8.58% year-on-year increase, with a net profit of 1.466 billion yuan and operating cash flow of 1.504 billion yuan, also up by 8.77% [1] - The company announced its first-ever third-quarter dividend since its listing, distributing 2 yuan per 10 shares, totaling 200 million yuan [1] Group 1: Technological Advancements - Yuyue Medical has embraced technological innovation, applying AI and other cutting-edge technologies in product development and operational management, with R&D investment reaching 445 million yuan, a 9.76% increase [1] - The company launched over 30 significant new products, with its CGM new product algorithm utilizing AI technology, achieving key technical indicators at a global leading level [1] - During the 618 shopping festival, the sales of Yuyue Medical's CGM new products on JD.com increased by 165% year-on-year, significantly boosting its market share in the blood glucose management sector [1] Group 2: Profitability and Market Recognition - The gross profit margin for Yuyue Medical rose to 50.35% in the first three quarters of this year, reflecting strong market recognition for its high-end products both domestically and internationally [2] - The company is focusing on two core development directions: digitalization and wearability, aiming to advance the development of wearable devices for health monitoring [2] - The integration of AI technology is expected to enhance the efficiency of chronic disease prevention and health management, addressing issues related to insufficient medical resources and healthcare personnel shortages [2] Group 3: International Expansion - Yuyue Medical is accelerating its internationalization strategy, having established subsidiaries in Europe, Asia, and North America, with plans to expand into South America and the Middle East [3] - The company recently established a subsidiary in Indonesia, aiming to replicate its localized market approach successfully implemented in Thailand [3] - Yuyue Medical has participated in major medical exhibitions across several countries and formed a scientific advisory committee in Europe to enhance its brand image and gain local trust [3] - The overseas market growth rate has surpassed that of the domestic market, with significant breakthroughs in key markets like the USA and Thailand [3]

Core Viewpoint - Yuyue Medical (002223) reported a revenue of 6.545 billion yuan for the first three quarters of 2025, reflecting a year-on-year growth of 8.58% and a net profit attributable to shareholders of 1.466 billion yuan [1] Financial Performance - The company's revenue for the first three quarters reached 6.545 billion yuan, marking an 8.58% increase compared to the previous year [1] - The net profit attributable to shareholders was reported at 1.466 billion yuan [1] Dividend Announcement - Yuyue Medical plans to implement its first-ever third-quarter dividend since its listing, proposing a cash dividend of 2 yuan per 10 shares (including tax) [1] - The total cash dividend to be distributed amounts to 200 million yuan [1]

Group 1 - The core point of the article is that Yuyue Medical (SZ 002223) held a temporary board meeting on October 24, 2025, to review the Q3 2025 report and other documents [1] - For the first half of 2025, Yuyue Medical's revenue composition is as follows: respiratory therapy solutions accounted for 35.93%, clinical instruments and rehabilitation solutions 24.35%, home health testing solutions 21.77%, blood glucose management and POCT solutions 14.48%, and emergency solutions and others 2.92% [1] - As of the report date, Yuyue Medical's market capitalization is 37.2 billion yuan [1]

Group 1 - The core viewpoint of the article highlights Yuyue Medical's third-quarter performance, showing a revenue increase but a decline in net profit and earnings per share [1] Group 2 - Yuyue Medical reported approximately 6.545 billion yuan in revenue for the first three quarters of 2025, representing an 8.58% year-on-year increase [1] - The net profit attributable to shareholders was about 1.466 billion yuan, reflecting a 4.28% decrease compared to the previous year [1] - The basic earnings per share stood at 1.4687 yuan, down 4.47% year-on-year [1] - As of the report, Yuyue Medical's market capitalization was 37.2 billion yuan [1]

Core Viewpoint - Yuyue Medical reported a third-quarter revenue of 1.886 billion yuan, representing a year-on-year increase of 9.63%, while net profit decreased by 35.99% [1] Financial Performance - The revenue for the first three quarters reached 6.545 billion yuan, showing a year-on-year growth of 8.58% [1] - Net profit for the first three quarters was 1.466 billion yuan, reflecting a year-on-year decline of 4.28% [1]

江苏鱼跃医疗设备股份有限公司（以下简称"公司"）于 2025 年 10 月 24 日召开第六届董事会第十二次临时会议、第六届监事会第五次临时会议，审议通 过了关于《公司 2025 年前三季度利润分配方案》的议案，根据《公司法》《深 圳证券交易所股票上市规则》《公司章程》等相关规定，该议案尚需提交公司股 东大会审议通过。 基于公司董事会工作总体安排，公司董事会决定择期召开股东大会，届时将 另行发布股东大会的通知，提请股东大会审议上述议案。 特此公告。 江苏鱼跃医疗设备股份有限公司董事会 二〇二五年十月二十五日 证券代码：002223 证券简称：鱼跃医疗 公告编号：2025-038 江苏鱼跃医疗设备股份有限公司 关于择期召开股东大会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 ...

江苏鱼跃医疗设备股份有限公司 第六届监事会第五次临时会议决议公告 证券代码：002223 证券简称：鱼跃医疗 公告编号：2025-035 表决结果：同意：7 票；反对：0 票；弃权：0 票 监事会认为：经审核，公司 2025 年前三季度利润分配方案符合相关法律、 法规以及《公司章程》的规定，兼顾了投资者的利益和公司持续发展的资金需求， 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 2025 年 10 月 24 日，江苏鱼跃医疗设备股份有限公司（以下简称"公司"） 以通讯表决的方式召开了第六届监事会第五次临时会议。公司于 2025 年 10 月 19 日以书面送达及电子邮件方式向公司全体监事发出了召开公司第六届监事会 第五次临时会议的通知以及提交审议的议案。会议应到监事 7 名，实到监事 7 名。本次会议的召集、召开符合《中华人民共和国公司法》和《公司章程》的有 关规定，会议决议合法、有效。会议由公司监事会主席吕英芳先生主持，经与会 监事充分讨论，审议通过了如下议案： 二、监事会会议审议情况 1、关于《公司2025年第三季度报告》的议案 ...

证券代码：002223 证券简称：鱼跃医疗 公告编号：2025-034 江苏鱼跃医疗设备股份有限公司 第六届董事会第十二次临时会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 2025 年 10 月 24 日，江苏鱼跃医疗设备股份有限公司（以下简称"公司"）以通讯 表决的方式召开了第六届董事会第十二次临时会议。公司于 2025 年 10 月 19 日以书面 送达及电子邮件方式向公司全体董事发出了召开公司第六届董事会第十二次临时会议 的通知以及提交审议的议案。会议应出席董事 9 名，实际出席会议董事 9 名。本次会议 的召集、召开及表决等程序符合《中华人民共和国公司法》和《公司章程》的有关规定， 会议决议合法、有效。会议由董事长吴群先生主持，经与会董事充分讨论，审议通过了 如下议案： 二、董事会会议审议情况 1、 关于《公司 2025 年第三季度报告》的议案 表决结果：同意：9 票；反对：0 票；弃权：0 票 本议案中公司 2025 年第三季度财务报表已经公司董事会审计委员会审议通过。 《江苏鱼跃医疗设备股份有限公司 2025 ...

重要内容提示： 江苏鱼跃医疗设备股份有限公司 2025 年第三季度报告 证券代码：002223 证券简称：鱼跃医疗 公告编号：2025-036 2025 年第三季度报告 江苏鱼跃医疗设备股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 是 □否 追溯调整或重述原因 会计政策变更 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大 遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完 整。 3.第三季度财务会计报告是否经过审计 □是 否 1 江苏鱼跃医疗设备股份有限公司 2025 年第三季度报告 | | | 上年同期 | | 本报告 期比上 | 年初至报告 | | | 年初至 报告期 末比上 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | ...